Clofazimine-induced bull's-eye retinopathy. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Clofazimine-induced bull's-eye retinopathy.

Retina. 1986 Winter-Spring;6(1):50-2. Unique Identifier : AIDSLINE MED/86207305
Craythorn JM; Swartz M; Creel DJ

Abstract: Bull's-eye retinopathy has multiple associations. We report a case of bull's-eye retinopathy presumed to be secondary to clofazimine (Lamprene) treatment of a 30-year-old patient with acquired immunodeficiency syndrome (AIDS). Pretreatment baseline eye exam of this patient was normal except for bilateral cotton-wool spots. However, follow-up exam 5 months later revealed bilateral anterior pigmentary corneal deposits in a whorl pattern, a presumed infectious retinitis in the left eye, and bilateral annular macular pigmentary abnormalities. The patient was taken off clofazimine treatment, but died 1 month later. The authors suggest that patients being treated with clofazimine be examined for drug-related corneal and retinal lesions.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Case Report Clofazimine/*ADVERSE EFFECTS/THERAPEUTIC USE Fluorescein Angiography Fundus Oculi Human Macula Lutea/PATHOLOGY Male Mycobacterium Infections/COMPLICATIONS/DRUG THERAPY Pigmentation Disorders/CHEMICALLY INDUCED Retinitis Pigmentosa/*CHEMICALLY INDUCED/PATHOLOGY Skin Diseases/CHEMICALLY INDUCED Support, U.S. Gov't, Non-P.H.S. JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/complicationsadultcasereportclofazimine/KWDadverseeffects/therapeuticusefluoresceinangiographyfundusoculihumanmaculalutea/pathologymalemycobacteriuminfections/complications/drugtherapypigmentationdisorders/chemicallyinducedretinitispigmentosa/KWDchemicallyinduced/pathologyskindiseases/chemicallyinducedsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDjournalarticle
860830
M8680241

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .